Will the latecomer cancer immunotherapy ‘Jemperli (dostarlimab)’ from GSK be reimbursed as the first cancer immunotherapy in endometrial cancer? With cancer immunotherapies changing the treatment paradigm for the first time in decades, the demand in the field to speed up the reimbursement progress has also been increasing. in the field.

According to industry sources on the 30th, GSK has applied for the reimbursement of Jemperli to the Health Insurance Review and Assessment Service and is awaiting the application to be deliberated by the Cancer Disease Deliberation Committee. Therefore, whether the agenda will be deliberated by the CDDC is receiving attention.

Jemperli is the 7th approv